Determine feasibility of Provenge plus low-dose Cyclophosphamide as well as the immune efficacy of Provenge alone versus Provenge plus low-dose Cyclophosphamide and anti PD1 monoclonal antibodies (CT011) on the change in specific immune response...
Determine whether the combination of low dose-Cyclophosphamide and anti PD1 monoclonal antibodies (CT-011) with Provenge(tm) lead to improvement in increase progression free survival (PFS) and Overall Survival (OS) in patients with advanced, min...
18 Years and older (Adult, Senior)
August 22, 2011
September 18, 2017
Georgia Regents University Augusta, Georgia, United States
† Study has passed its completion date and status has not been verified in more than two years.